サンプル依頼リスト カート
  • English
  • Korean
表紙：胆嚢がん治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1297794

胆嚢がん治療の世界市場-2023年～2030年

Global Gall Bladder Cancer Treatment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
胆嚢がん治療の世界市場-2023年～2030年
出版日: 2023年06月15日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

胆嚢がん治療市場規模は2022年に7,950万米ドルに達し、2030年には1億2,140万米ドルまで成長すると予測されています。世界の胆嚢がん治療市場は、予測期間2023年から2030年にかけてCAGR 5.5%で推移しています。

胆嚢がん治療市場は、がん治療薬市場全体の一分野であり、胆嚢がんの治療に焦点を当てています。手術、化学療法、放射線療法、標的療法、免疫療法など、さまざまな治療法が含まれます。

この市場は、新たな治療アプローチや治療法の革新が現れるにつれて進化し続けています。継続的な研究、臨床試験、ヘルスケアプロバイダー、調査研究者、製薬企業間のコラボレーションが市場の将来を形成すると予想されます。

胆のうがん治療市場は、胆のうがんの有病率の増加、治療選択肢に対する認知度の向上、治療選択肢の研究開発の増加、有利な償還政策、高度診断施設の導入増加、技術の進歩などの要因によって牽引されています。

市場力学

高度診断施設の採用増加

胆のうがん治療における高度診断施設の採用増加は、市場シェアを牽引すると予想されます。高度診断施設は、胆嚢がんの早期発見、正確な診断、病期分類において重要な役割を果たしています。

さらに、分子検査やバイオマーカー解析を含む高度診断技術は、胆嚢がん治療における個別化医療アプローチに貢献しています。これらの技術は、特定の遺伝子変異、バイオマーカー、あるいは腫瘍の分子的特徴を同定するのに役立ち、標的治療やオーダーメイドの治療計画を可能にします。例えば、循環miR-141は胆嚢がんの診断、予後、治療標的のための潜在的なバイオマーカーです。

治療の選択肢における研究と開発の増加

胆嚢がんの治療法を進歩させるためには、研究開発の努力が不可欠です。現在進行中の研究開発は、胆嚢がんの根本的なメカニズムの理解、新たな治療標的の同定、革新的な治療アプローチの開発に焦点を当てています。

標的治療の出現は、胆嚢がんを含むがん治療に革命をもたらしました。研究者は特定の分子標的を同定し、これらの標的を選択的に阻害または破壊する薬剤を開発することで、より効果的で毒性の低い治療法へと導いています。標的療法は、個々の患者の分子特性に合わせた、個別化された正確な治療オプションの可能性を提供します。

例えば、2023年3月、公立の大学院医学研究大学であるPGIMER Chandigarhが、末期の胆嚢がんの治療法として不可逆的エレクトロポレーション法の臨床試験を開始しました。この方法では、がん腫瘍に高電圧の短時間電気パルスを与えて腫瘍細胞を破壊し、治癒を可能にします。

限られた治療オプション

他のがんと比較して、胆嚢がんは特に進行がんや転移がんの場合、治療の選択肢が限られています。限られた治療選択肢は、最適な治療結果や患者の奏効率の低下につながる可能性があります。既存の治療法の有効性が限定的であったり、患者が抵抗性を示したりした場合、ヘルスケアプロバイダーが利用できる選択肢が制限され、患者の転帰や満足度に影響を及ぼす可能性があります。

胆嚢がんは様々なサブタイプや分子的特徴を持つ複雑な疾患です。限られた治療選択肢では、疾患の不均一性に十分に対応できない可能性があり、患者ごとに個別化された的確な治療アプローチを提供することは困難です。

COVID-19の影響分析

COVID-19の大流行は、胆嚢がん治療市場を含むヘルスケア産業に大きな影響を与えました。世界中のヘルスケアシステムがCOVID-19患者の管理に追われています。胆嚢がんの手術を含む緊急性のない処置は、多くの場合延期または中止され、治療の遅れや中断につながっています。このことは、胆嚢がん患者の適時の治療開始に影響を及ぼしています。

パンデミックは、COVID-19感染のリスクを最小化し、ヘルスケア資源を最適化するために、治療アプローチの変更を必要としました。場合によっては、外科的治療が全身療法や放射線療法などの代替治療法に取って代わられたり、延期されたりしています。このような変化は、胆嚢がん患者の全体的な管理と転帰に影響を与える可能性があります。

ロシア・ウクライナ紛争分析

ロシアとウクライナの紛争は胆嚢がん治療市場に大きな影響を与えました。競合はサプライチェーンを混乱させ、医薬品、手術機器、診断ツールなどの必要不可欠な医療用品の入手を妨げる可能性があります。これらの供給物資の不足やアクセスの制限は、胆嚢がん患者に提供される医療の質に影響を与え、最適な治療結果をもたらさない可能性があります。

紛争状況は、医療従事者の移住や転居につながり、ヘルスケアシステムをさらに緊張させる可能性があります。熟練した医療従事者の喪失は、胆嚢がん患者に適切で専門的なケアを提供する能力に影響を与える可能性があります。さらに、ヘルスケア従事者は紛争中に医学教育やトレーニングの機会を得ることが困難になり、最新のケアを提供する能力に影響を及ぼす可能性があります。

目次

第1章 調査手法と範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響を与える要因
    • 促進要因
      • 高度な診断設備の採用の増加
      • 治療選択肢の調査開発の増加
    • 抑制要因
      • 副作用のリスクが高い
      • 高額な治療費
      • 限られた治療選択肢
    • 機会
      • 治療手順における技術の進歩
    • 影響分析

第5章 業界分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19の分析

第7章 治療別

  • 化学療法
  • 免疫療法
  • 放射線治療
  • その他

第8章 適応症別

  • ステージ I
  • ステージ II
  • ステージⅢ
  • ステージ IV

第9章 エンドユーザー別

  • 病院
  • 婦人科クリニック
  • 学術センター
  • 研究センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東とアフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • 合併と買収の分析

第12章 企業プロファイル

  • Eli Lilly and Company
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Sanofi Inc.
  • OncoTherapy Science Inc.
  • Intuitive Surgical Inc.
  • GLS Pharma Ltd.
  • Sun Pharmaceutical Industries Ltd.

第13章 付録

目次
Product Code: PH4702

Market Overview

The Gall Bladder Cancer Treatment Market size reached US$ 79.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$121.4 million by 2030. The Global Gall Bladder Cancer Treatment Market is exhibiting at a CAGR of 5.5% during the forecast period 2023-2030.

The Gall Bladder Cancer Treatment Market is a segment of the overall oncology therapeutics market, focusing on treating gallbladder cancer. It involves various modalities such as surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy.

The market continues to evolve as new treatment approaches and therapeutic innovations emerge. Ongoing research, clinical trials, and collaborations among healthcare providers, researchers, and pharmaceutical companies are expected to shape the market's future.

The gall bladder cancer treatment market is driven by factors such as the increasing prevalence of gall bladder cancer, increasing awareness of treatment options, increasing research and developments in treatment options, favorable reimbursement policies, increasing adoption of advanced diagnostic facilities, and technological advancements.

Market Dynamics

Increasing Adoption of Advanced Diagnostic Facilities

The increasing adoption of advanced diagnostic facilities for gall bladder cancer treatment is expected to drive the market share. Advanced diagnostic facilities play a crucial role in the early detection, accurate diagnosis, and staging of gallbladder cancer.

Furthermore, advanced diagnostic techniques, including molecular testing and biomarker analysis, contribute to personalized medicine approaches in gallbladder cancer treatment. These techniques help identify specific genetic mutations, biomarkers, or molecular characteristics of the tumor, enabling targeted therapies and tailored treatment plans. For instance, Circulating miR-141 as a potential biomarker for diagnosis, prognosis, and therapeutic targets in gallbladder cancer.

Increasing Research and Developments in Treatment Options

Research and development efforts are vital in advancing treatment options for gallbladder cancer. Ongoing research activities focus on understanding the underlying mechanisms of gallbladder cancer, identifying new therapeutic targets, and developing innovative treatment approaches.

The emergence of targeted therapies has revolutionized cancer treatment, including gallbladder cancer. Researchers are identifying specific molecular targets and developing drugs that selectively inhibit or disrupt these targets, leading to more effective and less toxic treatments. Targeted therapies offer the potential for personalized and precise treatment options tailored to individual patients' molecular characteristics.

For instance, in March 2023, PGIMER Chandigarh, a public postgraduate medical research university started trials of irreversible electroporation for the treatment of late-stage gallbladder cancer through the procedure, the cancer tumor is given short-term electric pulses with high voltage to break tumor cells; allowing healing.

Limited Treatment Options

Compared to other types of cancer, gallbladder cancer has limited treatment options, especially for advanced or metastatic cases. Limited treatment options may lead to suboptimal treatment outcomes and lower patient response rates. If existing treatments have limited efficacy or patients develop resistt can restrict the options available to healthcare providers, potentially impacting patient outcomes and satisfaction.

Gallbladder cancer is a complex disease with various subtypes and molecular characteristics. Limited treatment options may not adequately address the heterogeneity of the disease, making it challenging to provide personalized and precise treatment approaches for each patient.

COVID-19 Impact Analysis

The COVID-19 pandemic profoundly impacted the healthcare industry, including the gallbladder cancer treatment market. Healthcare systems around the world have been overwhelmed with the management of COVID-19 patients. Non-urgent procedures, including surgeries for gallbladder cancer, have been postponed or canceled in many cases, leading to treatment delays and interruptions. This has affected the timely initiation of treatment for patients with gallbladder cancer.

The pandemic has necessitated changes in treatment approaches to minimize the risk of COVID-19 transmission and optimize healthcare resources. In some cases, surgical interventions may have been replaced or delayed by alternative treatment modalities such as systemic or radiation therapy. These changes may impact the overall management and outcomes of gallbladder cancer patients.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict had a significant impact on the gallbladder cancer treatment market. The competition can disrupt supply chains and hinder the availability of essential medical supplies, including medications, surgical equipment, and diagnostic tools. Shortages or limited access to these supplies can impact the quality of care provided to gallbladder cancer patients, potentially leading to suboptimal treatment outcomes.

Conflict situations can lead to the migration or displacement of healthcare professionals, which can further strain the healthcare system. The loss of skilled medical personnel can impact the capacity to provide adequate and specialized care for gallbladder cancer patients. Additionally, healthcare workers may face challenges in accessing medical education and training opportunities during conflict, which can affect their ability to provide up-to-date care.

Segment Analysis

The Global Gall Bladder Cancer Treatment Market is segmented based on treatment, indication, end-user, and region.

Based on Treatment, the Chemotherapy Segment is Expected to Dominate the Market Share

The market for chemotherapy holds 38.2% of the global gallbladder cancer treatment market share in 2022. Chemotherapy plays an important role in treating gallbladder cancer, both as a primary treatment option and as part of a multimodal approach.

In cases of advanced or metastatic gallbladder cancer where curative surgical options are limited, chemotherapy serves as a palliative treatment to control symptoms, prolong survival, and enhance the quality of life for patients. Palliative chemotherapy can help shrink tumors, alleviate pain, and manage other cancer-related symptoms, offering relief to patients.

For instance, in May 2023, Genome & Company will revise its strategy in developing a biliary tract cancer treatment candidate, GEN-001. The company plans to confirm the treatment effect of its combined use with cytotoxic chemotherapies by reflecting on cancer's secondary treatment trend. The company had submitted applications for changing its investigational new drug (IND) plan for the domestic phase 2 clinical trial of GEN-001 to the Ministry of Food and Drug Safety.

Geographical Analysis

North America Holds the Largest Market Share Due to the High Disease Burden and Advanced Diagnostic Facilities

North America holds the 41.2% market share for the Gall Bladder Cancer Treatment Market in 2022 due to the high disease burden and advanced diagnostic facilities. North America has reported a relatively higher incidence of gallbladder cancer than other parts of the world. Factors such as lifestyle, obesity rates, and genetic predisposition may contribute to the higher disease burden in this region. The larger patient population translates to a greater demand for gallbladder cancer treatment, leading to a larger market share.

North America is known for its advanced healthcare infrastructure and diagnostic capabilities. The region has well-established medical facilities, including hospitals, clinics, and imaging centers, equipped with state-of-the-art technologies for early detection and accurate diagnosis of gallbladder cancer. This early detection facilitates the timely initiation of treatment and improves patient outcomes.

Competitive Landscape

The major global players in the market include: Eli Lilly and Company, Bristol-Myers Squibb Company, Cipla Inc, Pfizer Inc, F. Hoffmann-La Roche Ltd, Sanofi Inc, OncoTherapy Science Inc, Intuitive Surgical Inc, GLS Pharma Ltd, and Sun Pharmaceutical Industries Ltd.

Why Purchase the Report?

  • To visualize the Global Gall Bladder Cancer Treatment Market segmentation based on treatment, indication, end-user, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous gall bladder cancer treatment market-level data points with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Gall Bladder Cancer Treatment Market Report Would Provide Approximately 54 Tables, 46 Figures And 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment
  • 3.2. Snippet by Indication
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Adoption of Advanced Diagnostic Facilities
      • 4.1.1.2. Increasing Research and Developments in Treatment Options
    • 4.1.2. Restraints
      • 4.1.2.1. Higher Risk of Adverse Effects
      • 4.1.2.2. High Cost of Treatment
      • 4.1.2.3. Limited Treatment Options
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological advancements in treatment procedures
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 7.1.2. Market Attractiveness Index, By Treatment
  • 7.2. Chemotherapy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Immunotherapy
  • 7.4. Radiation Therapy
  • 7.5. Others

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Stage I*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Stage II
  • 8.4. Stage III
  • 8.5. Stage IV

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Gynecology Clinics
  • 9.4. Academic Centers
  • 9.5. Research Centers
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Eli Lilly and Company*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Bristol-Myers Squibb Company
  • 12.3. Cipla Inc.
  • 12.4. Pfizer Inc.
  • 12.5. F. Hoffmann-La Roche Ltd.
  • 12.6. Sanofi Inc.
  • 12.7. OncoTherapy Science Inc.
  • 12.8. Intuitive Surgical Inc.
  • 12.9. GLS Pharma Ltd.
  • 12.10. Sun Pharmaceutical Industries Ltd.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us